Biostar stock: buy or sell?

BSPM stock price: $0.07 0.00% At close on May 14th, 2020

Updated on:
May 14th, 2020

0

Biostar Pharmaceuticals shares remained constant 0.00% to $0.07 today. On April/23 BSPM plummed a frightening -100.00%. On April 21st BSPM climbed an outstanding 50.00%. Counting Thursday, it's been 4 green days in a row, soaring $0.00 or 0.00%.

Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China.

Should I buy Biostar stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Following a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Currently, Biostar stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean BSPM will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Biostar stock a buy?

Financial institutions and banks publish stock ratings everyday. Unfortunately, we couldn't find any rating for BSPM stock for the last month.

Biostar stock analysis

Daily outlook

Shares of Biostar Pharmaceuticals closed today at $0.07 and remained constant a tight 0.00%.

Shares of Biostar Pharmaceuticals ended today at $0.07 and remained constant a tight 0.00%. BSPM is soaring again after a 64.71% correction from its last top on March at $0.17.

BSPM stock chart (daily)

Weekly outlook

Biostar shares stayed stable 0.00% this week, ending at $0.07. Early April BSPM collapsed a spooky -85.71% in just one week. Late March BSPM rocketed a dazzling 23.08% in just one week. With this, it's been 4 green weeks in a row, gaining $0.00 or 0.00%.

Weekly chart tells us that price is in a simple uptrend, tested $0.06 level and now climbing back aiming its last top at $0.17.

BSPM stock chart (weekly)

Biostar stock price history

Biostar IPO was on December 29th, 2009 at $81.90 per share1. Since then, BSPM stock lost a -99.90%, with a yearly average of -10.00%.

1: Adjusted price after possible price splits or reverse-splits.

Biostar stock historical price chart

BSPM stock reached 52-week highs at $3.47, and all-time highs 2010-04-23 with a price of 115.71.

Biostar stock price target

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' BSPM stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we have not detected any price target for Biostar Pharmaceuticals stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

After presenting its last earnings report , Biostar . Unfortunately, reported EPS is not yet available in our database.
BSPM earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2016-Q3-n/a-0.71n/a
2016-Q4-n/a1.33n/a
2017-Q1-n/a-0.38n/a
2017-Q22017-11-15n/a-0.5n/a
2017-Q32017-11-20n/a-0.05n/a
2017-Q42018-04-12n/an/an/a
2018-Q12018-07-06n/an/an/a

Annual financial results

In 2016, Biostar Pharmaceuticals annual turnover plunged a chilling -91.21% to $2.38 million USD from $27.13 marked in 2015. In the same way, its income margin (compared to sales) collapsed to -238.98%, that is $-5.70 million.

BSPM annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2012$49 M-$-20.00 M-40.6%-
2013$53 M6.91%$0.81 M1.5%-104.05%
2014$61 M16.48%$4.85 M7.9%499.25%
2015$27 M-55.83%$-25.11 M-92.6%-617.98%
2016$2.38 M-91.21%$-5.70 M-239.0%-77.31%

Quarterly financial results

Reported quarter earnings marked M with a profit margin of . Profit margin remained steady a 0.00% compared to previous quarter when profit margin was nan%. When comparing revenues to same quarter last year, Biostar Pharmaceuticals sales marked a neutral movement and remained steady a nan%. Looking back to recent quarterly results, Biostar posted 6 positive quarters in a row.
BSPM quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2016-Q3$0.64 M-$-1.56 M-241.9%-
2016-Q4$0.32 M-50.72%$3.39 M1066.1%-317.18%

Biostar ownership

When you are planning to invest in shares of a company, it's worth to review its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Biostar Pharmaceuticals, 0.00% of all outstanding shares are owned by its staff.

In case of Biostar stock, 0.00% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for BSPM stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Biostar Pharmaceuticals:

BSPM
Market cap$0.2 M
Total shares2.6 M
Float shares2.2 M
  - Institutional holdings (%)0.0%
  - Insider holdings (%)0.0%
Shares in short selling0.0%

Biostar summary

Thursday, May 14th, 2020
Open$0.07
Close$0.07
Day range$0.07 - $0.07
Previous close$0.07
Session gain0.00%
Average true range$0.04
50d mov avg$0.11
100d mov avg$0.15
200d mov avg$0.64
Daily patternlb01a
Weekly pattern lb01a

Biostar performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We selected as the bechmarking frame for Biostar Pharmaceuticals stock.
Stock3m6m12m
BSPMBiostar Pharmaceu...-30.00%-53.33%-72.00%

Biostar competitors

Unfortunately, we could not find any public company that could be defined as Biostar Pharmaceuticals competitor. This doesn't mean Biostar Pharmaceuticals does not have any competitor in the market, it's just we could not detected it.